Neurocrine Bio. (NBIX) PT Raised to $100 at H.C. Wainwright on Positive Survey Data

February 16, 2017 7:47 AM

HC Wainwright and Co. analyst Andrew Fein reiterates Buy rating and raises price target on Neurocrine Biosciences (NASDAQ: NBIX) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found